AstraZeneca Stock Price, News & Analysis (NYSE:AZN)

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca announced a semiannual dividend on Friday, February 15th. Shareholders of record on Friday, March 1st will be paid a dividend of $0.95 per share on Wednesday, March 27th. This represents a yield of 4.64%. The ex-dividend date of this dividend is Thursday, February 28th. This is a boost from AstraZeneca's previous semiannual dividend of $0.45. View AstraZeneca's Dividend History.

AstraZeneca's stock split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were distributed to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

AstraZeneca plc (NYSE:AZN) posted its earnings results on Thursday, July, 25th. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.30 by $0.43. The business earned $5.72 billion during the quarter, compared to analysts' expectations of $5.57 billion. AstraZeneca had a return on equity of 35.83% and a net margin of 9.38%. The firm's revenue was up 10.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.69 earnings per share. View AstraZeneca's Earnings History.

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for AstraZeneca.

AstraZeneca issued an update on its FY19 earnings guidance on Thursday, July, 25th. The company provided EPS guidance of $3.50-3.70 for the period, compared to the Thomson Reuters consensus estimate of $3.54.

19 Wall Street analysts have issued 12 month price targets for AstraZeneca's shares. Their forecasts range from $40.73 to $50.00. On average, they expect AstraZeneca's share price to reach $46.1217 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price. View Analyst Price Targets for AstraZeneca.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 4 sell ratings, 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

Headlines about AZN stock have trended negative on Friday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. AstraZeneca earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for AstraZeneca.

AstraZeneca saw a increase in short interest in August. As of August 15th, there was short interest totalling 14,285,300 shares, an increase of 23.5% from the July 15th total of 11,567,200 shares. Based on an average daily trading volume, of 3,250,000 shares, the short-interest ratio is presently 4.4 days. Approximately 0.6% of the company's shares are short sold. View AstraZeneca's Current Options Chain.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), Eli Lilly And Co (LLY), AbbVie (ABBV), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), AT&T (T), AbbVie (ABBV), Bank of America (BAC), Cisco Systems (CSCO), Gilead Sciences (GILD), Merck & Co., Inc. (MRK), Micron Technology (MU), Intel (INTC) and QUALCOMM (QCOM).

AstraZeneca's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (2.29%), Jennison Associates LLC (1.34%), Bank of America Corp DE (0.70%), Fisher Asset Management LLC (0.63%), Price T Rowe Associates Inc. MD (0.50%) and Winslow Capital Management LLC (0.24%). View Institutional Ownership Trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Morgan Stanley, Bank of America Corp DE, Cidel Asset Management Inc., Renaissance Technologies LLC, Wells Fargo & Company MN, Cubist Systematic Strategies LLC and Winslow Capital Management LLC. View Insider Buying and Selling for AstraZeneca.

AZN stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Marshall Wace North America L.P., Primecap Management Co. CA, Marshall Wace LLP, Price T Rowe Associates Inc. MD, Balyasny Asset Management LLC, Fisher Asset Management LLC and Holocene Advisors LP. View Insider Buying and Selling for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $44.61.

AstraZeneca has a market capitalization of $117.05 billion and generates $22.09 billion in revenue each year. The company earns $2.16 billion in net income (profit) each year or $1.73 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.View Additional Information About AstraZeneca.

The official website for AstraZeneca is http://www.astrazeneca.com/.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]